Cargando…

Direct conversion from long‐acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept

Long‐acting testosterone replacement therapy (TRT) suppresses spermatogenesis. A short‐acting TRT, Natesto, maintains spermatogenesis in some men. This study evaluated hormonal and semen parameters converting men from long‐acting TRT to Natesto. Baseline hormones, again on long‐acting TRT and 1 mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavoussi, Parviz K., Machen, Graham L., Chen, Shu‐Hung, Gilkey, Melissa S., Chen, Justin, Hamzeh, Yazan, Aston, Kenneth I., Kavoussi, Shahryar K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542608/
https://www.ncbi.nlm.nih.gov/pubmed/35521891
http://dx.doi.org/10.1111/and.14453
_version_ 1784804189240557568
author Kavoussi, Parviz K.
Machen, Graham L.
Chen, Shu‐Hung
Gilkey, Melissa S.
Chen, Justin
Hamzeh, Yazan
Aston, Kenneth I.
Kavoussi, Shahryar K.
author_facet Kavoussi, Parviz K.
Machen, Graham L.
Chen, Shu‐Hung
Gilkey, Melissa S.
Chen, Justin
Hamzeh, Yazan
Aston, Kenneth I.
Kavoussi, Shahryar K.
author_sort Kavoussi, Parviz K.
collection PubMed
description Long‐acting testosterone replacement therapy (TRT) suppresses spermatogenesis. A short‐acting TRT, Natesto, maintains spermatogenesis in some men. This study evaluated hormonal and semen parameters converting men from long‐acting TRT to Natesto. Baseline hormones, again on long‐acting TRT and 1 month after converting to Natesto, as well as semen parameters 3 months after converting to Natesto were assessed. Twenty‐seven men were directly converted from long‐acting forms of TRT to Natesto. Mean duration on long‐acting TRT was 24.3 ± 19 months. Testosterone levels were similar on long‐acting forms of TRT and Natesto, however; E2 levels were significantly lower on Natesto. Ten men had semen analyses demonstrating azoospermia while on long‐acting TRT, the remainder were presumed to be azoospermic or severely oligospermic which has been well established as an effect of long‐acting TRT. All 27 men had resumption of spermatogenesis with a mean sperm concentration of 50.7 million/ml after converting to Natesto, considered within the fertile range. One couple achieved a pregnancy 4 months after converting to Natesto. Hypogonadal men on long‐acting TRT interested in resumption of spermatogenesis may convert directly to Natesto for an opportunity to do so while remaining on a form of TRT and achieving lower E2 levels.
format Online
Article
Text
id pubmed-9542608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95426082022-10-14 Direct conversion from long‐acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept Kavoussi, Parviz K. Machen, Graham L. Chen, Shu‐Hung Gilkey, Melissa S. Chen, Justin Hamzeh, Yazan Aston, Kenneth I. Kavoussi, Shahryar K. Andrologia Original Articles Long‐acting testosterone replacement therapy (TRT) suppresses spermatogenesis. A short‐acting TRT, Natesto, maintains spermatogenesis in some men. This study evaluated hormonal and semen parameters converting men from long‐acting TRT to Natesto. Baseline hormones, again on long‐acting TRT and 1 month after converting to Natesto, as well as semen parameters 3 months after converting to Natesto were assessed. Twenty‐seven men were directly converted from long‐acting forms of TRT to Natesto. Mean duration on long‐acting TRT was 24.3 ± 19 months. Testosterone levels were similar on long‐acting forms of TRT and Natesto, however; E2 levels were significantly lower on Natesto. Ten men had semen analyses demonstrating azoospermia while on long‐acting TRT, the remainder were presumed to be azoospermic or severely oligospermic which has been well established as an effect of long‐acting TRT. All 27 men had resumption of spermatogenesis with a mean sperm concentration of 50.7 million/ml after converting to Natesto, considered within the fertile range. One couple achieved a pregnancy 4 months after converting to Natesto. Hypogonadal men on long‐acting TRT interested in resumption of spermatogenesis may convert directly to Natesto for an opportunity to do so while remaining on a form of TRT and achieving lower E2 levels. John Wiley and Sons Inc. 2022-05-06 2022-09 /pmc/articles/PMC9542608/ /pubmed/35521891 http://dx.doi.org/10.1111/and.14453 Text en © 2022 The Authors. Andrologia published by Wiley‐VCH GmbH. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Kavoussi, Parviz K.
Machen, Graham L.
Chen, Shu‐Hung
Gilkey, Melissa S.
Chen, Justin
Hamzeh, Yazan
Aston, Kenneth I.
Kavoussi, Shahryar K.
Direct conversion from long‐acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept
title Direct conversion from long‐acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept
title_full Direct conversion from long‐acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept
title_fullStr Direct conversion from long‐acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept
title_full_unstemmed Direct conversion from long‐acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept
title_short Direct conversion from long‐acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept
title_sort direct conversion from long‐acting testosterone replacement therapy to natesto allows for spermatogenesis resumption: proof of concept
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542608/
https://www.ncbi.nlm.nih.gov/pubmed/35521891
http://dx.doi.org/10.1111/and.14453
work_keys_str_mv AT kavoussiparvizk directconversionfromlongactingtestosteronereplacementtherapytonatestoallowsforspermatogenesisresumptionproofofconcept
AT machengrahaml directconversionfromlongactingtestosteronereplacementtherapytonatestoallowsforspermatogenesisresumptionproofofconcept
AT chenshuhung directconversionfromlongactingtestosteronereplacementtherapytonatestoallowsforspermatogenesisresumptionproofofconcept
AT gilkeymelissas directconversionfromlongactingtestosteronereplacementtherapytonatestoallowsforspermatogenesisresumptionproofofconcept
AT chenjustin directconversionfromlongactingtestosteronereplacementtherapytonatestoallowsforspermatogenesisresumptionproofofconcept
AT hamzehyazan directconversionfromlongactingtestosteronereplacementtherapytonatestoallowsforspermatogenesisresumptionproofofconcept
AT astonkennethi directconversionfromlongactingtestosteronereplacementtherapytonatestoallowsforspermatogenesisresumptionproofofconcept
AT kavoussishahryark directconversionfromlongactingtestosteronereplacementtherapytonatestoallowsforspermatogenesisresumptionproofofconcept